Gonal-f RFF

See also: Generic Gonal-f, Generic Gonal-f RFF Pen

Gonal-f RFF is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):

GONAL-F RFF (follitropin alfa/beta - injectable; subcutaneous)

• 
  Manufacturer: EMD SERONO
  
  Approval date: March 25, 2004
  
  Strength(s): 75 IU/VIAL ^[RLD]

Has a generic version of Gonal-f RFF been approved?

No. There is currently no therapeutically equivalent version of Gonal-f RFF available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gonal-f RFF. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Follicle stimulating hormone and pharmaceutical compositions containing same
  Patent 5,767,067
  Issued: June 16, 1998
  Inventor(s): Arpaia; Guiseppe & Serani; Serenella & Sirna; Antonino & Villa; Stefano
  Assignee(s): Istituto di Ricerca Cesare Serono S.p.A.
  Purification of human FSH from post-menopausal urine gonadogropin using immunochromatography and reverse phase HPLC steps yelds a biologically active hormone which is free from detectable traces of LH and other urinary proteins.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  



• 
  Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
  Patent 5,767,251
  Issued: June 16, 1998
  Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
  Assignee(s): Genzyme Corporation
  Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
  
  Patent expiration dates:
  
  
  • June 16, 2015
    
    ✓ 
    Drug substance
  
  

See also...

• Gonal-f RFF Consumer Information (Cerner Multum)
• Gonal-f RFF Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
• Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
• Follitropin Beta Consumer Information (Wolters Kluwer)
• Follicle stimulating hormone Consumer Information (Cerner Multum)
• Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
• Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)